Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: A case-control study of 55 patients

Stroke

Volumn 29, Issue 12, 1998, Pages 2507-2510

  Lüdemann, Peter ^c   Nabavi, Darius G ^d   Junker, Ralf ^d   Wolff, Endrik ^d   Papke, Karsten ^d   Buchner, Helmut ^a   Assmann, Gerd ^b   Ringelstein, E Bernd ^d  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Leibniz Institute of Atherosclerosis Research   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d NONE

Author keywords

Factor V; Protein C; Sinus thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN VEIN; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0345367477     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.12.2507     Document Type: Article

References (32)

1. Marlar RA, Kleiss AJ, Griffin JH. Human protein C: inactivation of factor V and VIII in plasma by the activated molecule. Ann N Y Acad Sci. 1981; 370:303-310.
2. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004-1008.
3. Bertina RM, Koeleman BPMC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369:64-67.
4. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-1134.
5. Koster T, Rosendaal FR, de Ronde F, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet. 1993;342:1503-1506.
6. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
7. Bridey F, Wolf M, Laissy JP, Morin V, Lefebvre M, de Prost S. Fatal cerebral venous thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost. 1995;74:1379. Letter.
8. Bengtsson A, Zoller B, de Frutos PG, Dahlbäck B, Sturfelt G. Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus. Lupus. 1996;5:598-601.
9. Dulli DA, Luzzio CC, Williams EC, Schutta HS. Cerebral venous thrombosis and activated protein C resistance. Stroke. 1996;27: 1731-1733.
10. Nowak-Göttl U, Koch HG, Aschka I, Kohlhase B, Vielhaber H, Kurlemann G, Oleszuk-Raschke K, Kehl HG, Jürgens H, Schneppenheim R. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol. 1996;92:992-998.
11. Vuillier F, Moulin T, Tatu L, Rumbach L, Bertrand MA. Isolated cortical vein thrombosis and activated protein C resistance. Stroke. 1996;27: 1440-1441. Letter.
12. Sánchez del Rio M, Gómez-Tortosa E, Outeriño J. Cerebral venous thrombosis and activated protein C resistance. J Neurol. 1996;243: 727-728.
13. Samama MM, Simon D, Horellou MH, Trossaert M, Elalamy I, Conrad J. Diagnosis and clinical characteristics of inherited activated protein C resistance. Haemostasis. 1996;26(suppl 4):315-330.
14. Bontempo FA, Hassett AC, Faruki H, Steed DL, Webster MW, Makaroun MS. The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation. J Vasc Surg. 1997;25:271-275.
15. Crassard I, Biousse V, Bousser MG, Meyer B, Marsot-Dupuch K. Hearing loss and headache revealing lateral sinus thrombosis in a patient with factor V Leiden mutation. Stroke. 1997;28:876-878. Letter.
16. Zuber M, Arquizan C, Touzé E, Mas JL, Rondepierre P. Response. Stroke 1997;28:877-878. Letter.
17. Hallak M, Senderowicz J, Cassel A, Shapira C, Aghai E, Auslender R, Abramovici H. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol. 1997;176: 889-893.
18. Siegen CEH, Smelt AHM, de Bruin TWA. Activated protein C resistance and factor V Leiden mutation are risk factors for cerebral sinus thrombosis. Stroke. 1997;28:1291-1292. Letter.
19. Pohl M, Zimmerhackl LB, Heinen F, Sutor AH, Schneppenheim R, Brandis M. Bilateral renal vein thrombosis and venous sinus thrombosis in a neonate with factor V mutation (FV Leiden). J Pediatr. 1998;132:159-161.
20. Wilder-Smith E, Kothbauer-Margreiter I, Lammle B, Sturzenegger M, Ozdoba C, Hauser SP. Dural puncture and activated protein C resistance: risk factors for cerebral venous sinus thrombosis. J Neurol Neurosurg Psychiatry. 1997;63:351-356.
21. Deschiens MA, Conrad J, Horellou MH, Ameri A, Preter M, Chedru F, Samama MM, Bousser MG. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke. 1996;27:1724-1730.
22. Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke. 1996;27:1721-1723.
23. Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost. 1996;75:393-394.
24. de Bruijn SFTM, Stam J, Koopmann MMW, Vandenbroucke JP, for the Cerebral Venous Sinus Thrombosis Study Group. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in carriers of hereditary prothrombotic conditions. BMJ. 1998;316:589-592.
25. Weih M, Vetter B, Ziemer S, Mehraein S, Valdueza JM, Koscielny J, Kulozik AE, Einhäupl KM. Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis. J Neurol. 1998;245:149-152.
26. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338: 1793-1797.
27. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin. 1992: 10:87-111. Review.
28. Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506-Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399-403.
29. van den Belt AGM, Sanson BJ, Simioni P, Prandoni P, Büller HR, Girolami A, Prins MH. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med. 1997;157: 2227-2232.
30. Eichinger S, Pabinger I, Stumpflen A, Hirschl M, Bialonczyk C, Schneider B, Mannhalter C, Minar E, Lechner K, Kyrie PA. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997;77:624-628.
31. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E, for the Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997;336:393-398.
32. Hirsh J, Kearon C, Ginsberg J. Duration of anticoagulation therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med. 1997;157:2174-2177.